custirsen
Nucleic acidexperimental
Custirsen, usually supplied as its sodium salt, is an investigational drug that is under clinical testing for the treatment of cancer. It is an antisense oligonucleotide (ASO) targeting clusterin expression. In metastatic prostate cancer, custirsen showed no benefit in improving overall survival. — Wikipedia
Clinical trial activity
13 trials · 13 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
9
Phase 3
4
Phase 4
0
Earliest trial started Dec 1, 2002 (NCT00054106)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Heart Diseases · Phase 1
- Kidney Neoplasms · Phase 1
- Lung Neoplasms · Phase 1
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 1
- Prostatic Neoplasms · Phase 3
- Prostatic Neoplasms, Castration-Resistant · Phase 3
- Urinary Bladder Neoplasms · Phase 1
Mechanism of action
- Clusterin mRNAANTISENSE INHIBITOR
Clusterin mRNA antisense inhibitor
- Estrogen receptorMODULATOR
Estrogen receptor modulator
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCustirsen ↗
- ChEMBLCHEMBL2219773 ↗
- ChEMBLCHEMBL2108309 ↗
Also known as
- custirsen
- custirsen
- custirsen
- custirsen
- custirsen
- custirsen sodium
- custirsen sodium
- custirsen sodium
- isis-112989
- isis-112989
- ogx-011
- ogx-011
- ogx-011
- ogx-011
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01874561 | Phase 1 | May 1, 2013 | OncoGenex Technologies, Teva |
| NCT01630733 | Phase 3 | Sep 1, 2012 | OncoGenex Technologies |
| NCT01578655 | Phase 3 | Aug 1, 2012 | McMaster University, OncoGenex Technologies, Oregon Health and Science University, University of Paris |
| NCT01497470 | Phase 1 | Apr 1, 2012 | OncoGenex Technologies, Teva |
| NCT01188187 | Phase 3 | Nov 1, 2010 | British Columbia Cancer Agency, OncoGenex Technologies, Teva, University of London, University of Washington |
| NCT01083615 | Phase 3 | Mar 1, 2010 | McMaster University, OncoGenex Technologies, Oregon Health and Science University, Teva, University of Paris |
| NCT00327340 | Phase 2 | Jul 1, 2006 | OncoGenex Technologies, University of Montreal, University of Western Ontario |
| NCT00258375 | Phase 2 | Jun 1, 2005 | British Columbia Cancer Agency, Canadian Cancer Trials Group |
| NCT00258388 | Phase 2 | Jun 1, 2005 | British Columbia Cancer Agency, Canadian Cancer Trials Group |
| NCT00138918 | Phase 2 | Jun 1, 2005 | Department of Defense, University of British Columbia |
| NCT00138658 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2004 | British Columbia Cancer Agency, OncoGenex Technologies |
| NCT00471432 | Phase 1 | Mar 1, 2003 | British Columbia Cancer Agency, Canadian Cancer Trials Group |
| NCT00054106 | Phase 1 | Dec 1, 2002 | British Columbia Cancer Agency, Canadian Cancer Trials Group |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (13)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| OncoGenex Technologies | For profit | 8 | 8 | 3 | 2004 |
| British Columbia Cancer Agency | Academic/Hospital | 6 | 0 | 3 | 2002 |
| Canadian Cancer Trials Group | Academic/Hospital | 4 | 4 | 2 | 2002 |
| Teva | For profit | 4 | 0 | 2 | 2010 |
| McMaster University | Academic/Hospital | 2 | 0 | 1 | 2010 |
| Oregon Health and Science University | Academic/Hospital | 2 | 0 | 1 | 2010 |
| University of Paris | Academic/Hospital | 2 | 0 | 1 | 2010 |
| Department of Defense | Government | 1 | 0 | 1 | 2005 |
| University of British Columbia | Academic/Hospital | 1 | 1 | 1 | 2005 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2010 |
| University of Montreal | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of Washington | Academic/Hospital | 1 | 0 | 1 | 2010 |
| University of Western Ontario | Academic/Hospital | 1 | 0 | 1 | 2006 |
13 organizations
Page 1 / 1